<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582721</url>
  </required_header>
  <id_info>
    <org_study_id>NSI-TD-010</org_study_id>
    <nct_id>NCT04582721</nct_id>
  </id_info>
  <brief_title>PREFerred Neurostimulation MODdalities - PREFMOD Study</brief_title>
  <official_title>PREFerred Neurostimulation MODdalities to Treat Chronic Intractable Back Pain, A 3x3 Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Regionale di Lugano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Paolo Maino MD PhD, Sponsor Investigator</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Regionale di Lugano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective 3x3 crossover study with randomized treatment order, comparing the&#xD;
      short-term efficacy of conventional-spinal cord stimulation (CON-SCS) with subcutaneous&#xD;
      stimulatio, high frequency-spinal cord stimulation (HF-SCS), and Combination Therapy, in&#xD;
      patients with chronic intractable back pain (with or without leg pain).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be preselected for inclusion in this study at the pain management center of&#xD;
      Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC) Lugano, and will be&#xD;
      informed about study-details by a study clinician. After informed consent signature, the&#xD;
      participants with chronic intractable back or back and leg pain will be implanted with the&#xD;
      stimulation lead(s). The leads are initially connected to an external trial neurostimulator.&#xD;
      Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks&#xD;
      trial phase will follow. The first two days after the leads implant will be without&#xD;
      stimulation and thereafter alternating stimulation every week will start, randomly ordering&#xD;
      the treatments using a Williams design balanced for first-order carryover effects (i.e.&#xD;
      incorporating 6 different treatment orders), from:&#xD;
&#xD;
        -  1) CON-SCS with Subcutaneous stimulation&#xD;
&#xD;
        -  2) HF-SCS&#xD;
&#xD;
        -  3) Combination Therapy A patient's favored SCS mode, providing that there is at least&#xD;
           50% reduction in pain intensity on the NRS in the trial phase, will then be implanted&#xD;
           and patients will be followed up for 12 months.&#xD;
&#xD;
      Pain intensity and pain medication will be assessed with a pain diary at baseline and during&#xD;
      the trial phase and will be furthermore measured after 3, 6, and 12 months after the&#xD;
      implantation. Physical functioning, Pain Extent, Patient Global Impression of Change (PGIC),&#xD;
      and Satisfaction with stimulation treatment (SST) will be assessed during the trial phase and&#xD;
      will be furthermore measured after 3, 6, and 12 months after the Implantable Nerve Stimulator&#xD;
      (INS) implantation. The other secondary outcomes will be measured at baseline, and after 3, 6&#xD;
      and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>back pain intensity</measure>
    <time_frame>21 days</time_frame>
    <description>The difference in the intensity of back pain between the three neurostimulation modalities as measured by the numerical rating scale (NRS) from 0 to 10, where 0 is not pain and 10 is the maximum pain the person can experience, assessed at baseline and in the trial phase 21 days</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Chronic Low-back Pain</condition>
  <arm_group>
    <arm_group_label>CON-SCS with subcutaneous stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days Conventional Spinal Cord Stimulation with subcutaneous stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF-SCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days High Frequency Spinal Cord Stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days a combination of CON-SCS with subcutaneous stimulation and HF-SCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)</intervention_name>
    <description>the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:&#xD;
1) CON-SCS with Subcutaneous stimulation&#xD;
2) HF-SCS&#xD;
3) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months.</description>
    <arm_group_label>CON-SCS with subcutaneous stimulation</arm_group_label>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>HF-SCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older at inclusion&#xD;
&#xD;
          -  chronic, intractable back or back and leg pain during at least 6 months&#xD;
&#xD;
          -  pain intensity of ≥ 5 on a NRS (ranging from 0 to 10)&#xD;
&#xD;
          -  previous drug therapy unsuccessful&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychological disorders&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  Known immune-deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva Koetsier, MD PhD LLM</last_name>
    <phone>0041918119590</phone>
    <email>eva.koetsier@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Maino, MD PhD LLM</last_name>
    <phone>0041918119590</phone>
    <email>paolo.maino@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro del Dolore, Neurocentro, Opedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Maino, MD</last_name>
      <phone>091 811 63 37</phone>
      <email>Paolo.Maino@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Eva Koetsier, MD</last_name>
      <phone>091 81175 95</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Regionale di Lugano</investigator_affiliation>
    <investigator_full_name>Eva Koetsier MD PhD LLM</investigator_full_name>
    <investigator_title>MD PhD LLM</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

